The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly (NYSE:LLY)) and Wegovy (Novo Nordisk (NYSE:NVO)), just completed a clinical side-by-side trial. After 72 weeks of testing ...
The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly (NYSE:LLY)) and Wegovy (Novo Nordisk (NYSE:NVO)), just completed a clinical side-by-side trial. After 72 weeks of testing ...